Aimmune Therapeutics Inc (NASDAQ:AIMT) Director Patrick G. Enright acquired 15,593 shares of the business’s stock in a transaction dated Thursday, February 22nd. The shares were bought at an average cost of $32.00 per share, for a total transaction of $498,976.00. Following the transaction, the director now directly owns 22,869 shares in the company, valued at $731,808. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Aimmune Therapeutics Inc (NASDAQ:AIMT) traded down $2.61 during mid-day trading on Monday, hitting $30.11. 2,388,094 shares of the stock were exchanged, compared to its average volume of 916,687. Aimmune Therapeutics Inc has a one year low of $15.97 and a one year high of $42.00. The company has a market cap of $1,550.00 and a PE ratio of -14.55.
Institutional investors and hedge funds have recently bought and sold shares of the stock. First Republic Investment Management Inc. acquired a new stake in shares of Aimmune Therapeutics in the 4th quarter worth about $202,000. Virtu Financial LLC acquired a new stake in shares of Aimmune Therapeutics in the 4th quarter worth about $239,000. Daiwa SB Investments Ltd. raised its holdings in shares of Aimmune Therapeutics by 44.5% in the 4th quarter. Daiwa SB Investments Ltd. now owns 7,290 shares of the biotechnology company’s stock worth $276,000 after acquiring an additional 2,245 shares during the last quarter. Teacher Retirement System of Texas acquired a new stake in shares of Aimmune Therapeutics in the 4th quarter worth about $282,000. Finally, SG Americas Securities LLC raised its holdings in shares of Aimmune Therapeutics by 54.7% in the 3rd quarter. SG Americas Securities LLC now owns 8,430 shares of the biotechnology company’s stock worth $209,000 after acquiring an additional 2,979 shares during the last quarter. Institutional investors own 66.59% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3224135/aimmune-therapeutics-inc-aimt-director-patrick-g-enright-buys-15593-shares.html.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.